A blueprint approach for safe & efficient genome editing of T cells to sustainably combat several immune diseases and cancers related to B-cell pathology
Company Details
- Address
- Iga Nephropathy (Igan)—the Most Common Glomerulonephritis And A Leading Cause Of End-Stage Renal Disease. This Therapy Could Also Provide A Blueprint For Tackling Other Diseases With Selective B-Cell Pathogenesis
- Industry
- Hospitals And Health Care
- NAICS
-
Health Care and Social AssistanceSocial Assistance
- Website
- https://www.genetiga-horizon.eu/
- Keywords
- Siena.
- Competitors
- Institute for Medical Research and Occupational Health, Swiss Biotech Association, QUANTUM TECHNOLOGIES LIMITED, Centre for Human Genetics, Institute for Innovation and Technology (iit), Quality in Organ Donation - QUOD, AID Autoimmun Diagnostika GmbH, Weill Cornell Medicine, The DTU Alt Protein Project, Innovation Acta S.r.l..
Genetiga Questions
Genetiga's website is https://www.genetiga-horizon.eu/
Genetiga's LinkedIn profile is https://www.linkedin.com/company/genetiga
Genetiga's industry is
Hospitals and Health Care
Genetiga's top competitors are
Institute For Medical Research And Occupational Health,
Swiss Biotech Association,
Quantum Technologies Limited,
Centre For Human Genetics,
Institute For Innovation And Technology (Iit),
Quality In Organ Donation - Quod,
Aid Autoimmun Diagnostika Gmbh,
Weill Cornell Medicine,
The Dtu Alt Protein Project,
Innovation Acta S.r.l..
Genetiga's categories are Hospitals and Health Care
